Home › La Jolla Pharmaceutical Announces Positive Pre-Clinical Data For Oral Galectin-3 Inhibitor In Nonalcoholic Steatohepatitis (NASH)
 

Keywords :   


La Jolla Pharmaceutical Announces Positive Pre-Clinical Data For Oral Galectin-3 Inhibitor In Nonalcoholic Steatohepatitis (NASH)

2014-07-30 09:57:01| drugdiscoveryonline Home Page

La Jolla Pharmaceutical Company (the “Company” or “La Jolla”), a leader in the development of therapeutics targeting significant unmet life-threatening diseases,recently announced positive pre-clinical data for LJPC-1010 in non-alcoholic steatohepatitis (NASH). LJPC-1010 is a derivative of GCS-100, a carbohydrate inhibitor of galectin-3, which has shown activity in chronic kidney disease in a Phase 2 trial

Tags: data positive oral pharmaceutical

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
20.05Sheboygan Paint Company Appoints New Technical Sales Representative
20.05GK Hair Unveils Summer 2024s Must-Have Hair Trends
20.05Revlon Taps Under Armour\'s Tchernavia Rocker As New Chief People Officer
20.05Canada invests over $9.6M to prevent, prepare for African swine fever
20.05Dabbagh Named General Manager of Waldencast Ventures Glaze Brand
20.05Pretty Little Thing warned over 'misleading' ads
20.05Several pork priorities secured in House Farm Bill
20.05BT scraps digital landline switch deadline
More »